Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Ganymed Robotics SAS, a medical device company, focuses on the development of robotics technologies for orthopedic surgeons. It develops a therapeutic device to enhance surgical precision in knee replacement surgery. The company was incorporated in 2018 and is based in Paris, France.
Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for auto-immune and inflammatory diseases. Founded in June 2019, the company centers its research on CXCR4, identified as a master regulator of inflammation, which allows for the control of interferons by plasmacytoid dendritic cells. Ermium Therapeutics has secured an exclusive worldwide license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which has aided in advancing the project within an academic environment. The company has also been recognized for its innovative approach, having won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.
Charles helps men regain control over their daily health concerns by starting with their personal health. The company was founded in Paris, Ile-de-France, France in 2019.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Germitec SAS is a company focused on enhancing medical hygiene through advanced disinfection systems. It specializes in ultraviolet light high-level disinfection (UV-C HLD) technology, specifically designed for reprocessing non-lumen medical devices. By providing innovative solutions, Germitec aims to simplify the responsibilities of healthcare professionals, improving safety and efficiency while significantly reducing the risk of cross-infection in clinical settings.
DAMAE Medical SAS, founded in 2014 and based in Paris, France, specializes in developing advanced medical imaging technologies for dermatology. The company's flagship product, OCTAV, employs innovative optical imaging techniques to provide in vivo, cellular-level images of skin tissues, offering insights similar to traditional histology without requiring tissue excision or processing. This non-invasive approach enables dermatologists to assess the malignancy of skin tumors with precision and efficiency through simple contact with the skin's surface. By leveraging bio-photonics, DAMAE Medical aims to enhance diagnostic capabilities in dermatology, facilitating timely and accurate evaluations of skin cancer.
NaoX Technologies develops wireless headphones that listen to brain vibrations.
Armgo Pharma, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics for debilitating cardiac, skeletal muscular, and neurological disorders. The company specializes in calcium release channel stabilizers known as Rycals, which target the ryanodine receptor/calcium release channel located on the sarcoplasmic/endoplasmic reticulum of cells. These therapeutics are designed to address various conditions, including chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. Founded in 2004, Armgo Pharma is headquartered in Tarrytown, New York, with an additional office in New York City.
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders. We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate as in-lab sleep studies, at a fraction of the cost. Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases. Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.
Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR solution, the Naica System. This platform leverages advanced microfluidic technologies to enhance the accessibility and efficiency of genetic testing across various life sciences fields, including research and therapeutics. Stilla Technologies aims to simplify the polymerase chain reaction process, offering a flexible and user-friendly system that supports multiple chemistries and multiplex capabilities. By providing tools for high-resolution genetic analysis, the company empowers researchers to conduct more intuitive image analysis and data exploration.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.
Developer of a tele-expertise platform designed to facilitate phone-based medical verification for patients eligible for health insurance facilities. The company's platform allows medical institutions or private physicians to secure and value informal opinions, strengthen the links between first and second recourse, centralize and promote requests from correspondents, and discover and contact doctors and organizations, enabling clients to improve, secure, and enhance the opinions exchanged and automate administrative tasks.
SmartCatch brings value-added liquid biopsy technology to empower clinicians, researchers, and industry in the fight against cancer.
Arkhn is a platform specialist in healthcare data interoperability. Arkhn tackles the issue of accessing healthcare data.
Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.
Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.
Operator of a biotechnological therapeutic platform intended to provide financial assistance and operational excellence to early-stage projects. The company's platform identifies, selects, and incubates early-stage biotechnology projects that focus on selected therapeutic areas such as rare diseases, neurological disorders, oncology, and immunology, enabling startups to further develop their medicinal and drug research process.
Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Lucine is focused on transforming patient health, primarily in the area of pain management. The company has developed a mobile health application that measures, analyzes, and alleviates pain from the comfort of home. Utilizing advanced algorithms, the application identifies the nature of a patient's pain by analyzing facial expressions, vocal cues, and posture. Based on this real-time assessment, it personalizes treatment options, offering techniques such as exercises, relaxation methods, art therapy, and meditation. The application aims to provide relief within five minutes through innovative analgesic neurostimulation, empowering patients with chronic pain to manage their symptoms effectively.
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.
Corlieve Therapeutics SAS, a biotechnology company, develops therapeutic options to patients with severe neurological disorders. Its lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) using a gene therapy approach. The company’s program employs a novel AAV gene therapy approach for the treatment of refractory TLE and is based on science from INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. The company was incorporated in 2019 and is based in Paris, France.
Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. It specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus includes spinocerebellar ataxias, Huntington's disease, and Rett syndrome, which are characterized by progressive neurological decline and developmental challenges. Vico Therapeutics is committed to discovering and delivering innovative treatments that address the unmet medical needs of patients suffering from these severe conditions. Through its research and development efforts, the company seeks to provide effective therapeutic options for individuals affected by these disorders.
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functional status on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR solution, the Naica System. This platform leverages advanced microfluidic technologies to enhance the accessibility and efficiency of genetic testing across various life sciences fields, including research and therapeutics. Stilla Technologies aims to simplify the polymerase chain reaction process, offering a flexible and user-friendly system that supports multiple chemistries and multiplex capabilities. By providing tools for high-resolution genetic analysis, the company empowers researchers to conduct more intuitive image analysis and data exploration.
Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Tacalyx GmbH is an oncology company based in Berlin, Germany, specializing in the discovery and development of therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs) found on the surface of metastatic tumors. These carbohydrate antigens are unique to cancer cells, resulting from abnormal glycosylation processes that enhance tumor aggressiveness and immune evasion. Tacalyx leverages a technology platform that enables the synthesis and analysis of complex carbohydrate structures, facilitating the creation of novel immunotherapies. By focusing on these cancer-specific targets, Tacalyx aims to develop effective treatments for malignancies where existing therapies are inadequate, ultimately enhancing the ability of physicians to trigger robust anti-cancer responses.
FeetMe SAS is a medical technology company based in Paris, France, specializing in the development of innovative insoles designed for real-time foot pressure mapping, particularly for diabetic patients. Founded in 2013, the company's insoles incorporate pressure sensors that create detailed pressure maps, alerting patients and healthcare providers to potential changes in plantar pressure. FeetMe's products include connected insoles and mobile software that assess gait and mobility parameters in real-life settings, utilizing advanced algorithms and wireless technology. These solutions are marketed to pharmaceutical companies for clinical trials, as well as to hospitals and rehabilitation centers for mobility assessments and gait training. Ultimately, FeetMe aims to address the growing global issue of mobility disorders, facilitating better therapeutic evaluations and rehabilitation outcomes for patients.
Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for auto-immune and inflammatory diseases. Founded in June 2019, the company centers its research on CXCR4, identified as a master regulator of inflammation, which allows for the control of interferons by plasmacytoid dendritic cells. Ermium Therapeutics has secured an exclusive worldwide license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which has aided in advancing the project within an academic environment. The company has also been recognized for its innovative approach, having won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Alizé Pharma is a group of privately held biopharmaceutical companies specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer. It is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Alizé Pharma has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance. The company was founded on 2015.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR solution, the Naica System. This platform leverages advanced microfluidic technologies to enhance the accessibility and efficiency of genetic testing across various life sciences fields, including research and therapeutics. Stilla Technologies aims to simplify the polymerase chain reaction process, offering a flexible and user-friendly system that supports multiple chemistries and multiplex capabilities. By providing tools for high-resolution genetic analysis, the company empowers researchers to conduct more intuitive image analysis and data exploration.
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.
Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers a range of products, including the SteriSpine PS kit for spinal fractures and degenerative conditions, and the SteriSpine VA platform for kyphoplasty and cement systems. Additionally, Safe Orthopaedics provides ready-to-use instrumentation for lumbar and cervical cages, featuring products such as Cedar, Elm, and Walnut. With a focus on spinal surgery, the company serves both the French and international markets.
Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
FeetMe SAS is a medical technology company based in Paris, France, specializing in the development of innovative insoles designed for real-time foot pressure mapping, particularly for diabetic patients. Founded in 2013, the company's insoles incorporate pressure sensors that create detailed pressure maps, alerting patients and healthcare providers to potential changes in plantar pressure. FeetMe's products include connected insoles and mobile software that assess gait and mobility parameters in real-life settings, utilizing advanced algorithms and wireless technology. These solutions are marketed to pharmaceutical companies for clinical trials, as well as to hospitals and rehabilitation centers for mobility assessments and gait training. Ultimately, FeetMe aims to address the growing global issue of mobility disorders, facilitating better therapeutic evaluations and rehabilitation outcomes for patients.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.
Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers a range of products, including the SteriSpine PS kit for spinal fractures and degenerative conditions, and the SteriSpine VA platform for kyphoplasty and cement systems. Additionally, Safe Orthopaedics provides ready-to-use instrumentation for lumbar and cervical cages, featuring products such as Cedar, Elm, and Walnut. With a focus on spinal surgery, the company serves both the French and international markets.
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.
Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
DAMAE Medical SAS, founded in 2014 and based in Paris, France, specializes in developing advanced medical imaging technologies for dermatology. The company's flagship product, OCTAV, employs innovative optical imaging techniques to provide in vivo, cellular-level images of skin tissues, offering insights similar to traditional histology without requiring tissue excision or processing. This non-invasive approach enables dermatologists to assess the malignancy of skin tumors with precision and efficiency through simple contact with the skin's surface. By leveraging bio-photonics, DAMAE Medical aims to enhance diagnostic capabilities in dermatology, facilitating timely and accurate evaluations of skin cancer.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
OxThera AB is a biopharmaceutical company based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee. Founded in 2005, it focuses on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. The company's leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced in the body, and Oxazyme, a recombinant enzyme aimed at managing dietary oxalate and preventing kidney stone formation. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in treating primary hyperoxaluria. OxThera holds global patents for its innovative approaches using bacteria and enzymes to address hyperoxaluria, contributing to advancements in kidney disease management.
Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.
Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic
Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
BliNK Biomedical SAS is a biotechnology company based in Lyon, France, founded in 2014. The company specializes in the discovery and development of monoclonal antibodies aimed at treating life-threatening diseases, particularly in the field of immuno-oncology. Its lead program focuses on a monoclonal antibody that targets an immune checkpoint, enhancing the body's immune response against tumors. BliNK Biomedical employs a unique B cell technology platform that facilitates the selection and isolation of specific antibody-producing cells from various species, including humans and animals. This innovative approach allows researchers to efficiently identify and develop next-generation anti-tumor therapeutics targeting novel immuno-oncology and immune-checkpoint pathways.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.
OxThera AB is a biopharmaceutical company based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee. Founded in 2005, it focuses on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. The company's leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced in the body, and Oxazyme, a recombinant enzyme aimed at managing dietary oxalate and preventing kidney stone formation. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in treating primary hyperoxaluria. OxThera holds global patents for its innovative approaches using bacteria and enzymes to address hyperoxaluria, contributing to advancements in kidney disease management.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers a range of products, including the SteriSpine PS kit for spinal fractures and degenerative conditions, and the SteriSpine VA platform for kyphoplasty and cement systems. Additionally, Safe Orthopaedics provides ready-to-use instrumentation for lumbar and cervical cages, featuring products such as Cedar, Elm, and Walnut. With a focus on spinal surgery, the company serves both the French and international markets.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
ABM Pharma is a partner of the entire pharmacy network in the home care of patients, today more than 5000 pharmacies are clients. ABM Pharma technicians work with more than 30,000 patients.
Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.
PathoQuest SAS is a biotechnology company based in Paris, France, focused on advancing pathogen detection through a metagenomics approach. Founded in 2010 as a spin-off from Institut Pasteur, the company utilizes proprietary next-generation sequencing (NGS) technology to provide actionable reports for clinicians, biologists, and biopharmaceutical professionals. PathoQuest’s offerings include the iDTECTTM Dx Blood test for pathogen identification and a comprehensive database that enhances diagnostic accuracy. Additionally, the company provides Viral Safety testing services specifically designed for biopharmaceutical firms, which has quickly established a revenue stream from major industry players. The integration of advanced sample preparation and cloud-based bioinformatics enables improved detection capabilities across various biological samples, allowing healthcare professionals to address the limitations of traditional infectious agent detection methods.
Meiogenix SAS is a biotechnology company based in Paris, France, that specializes in developing breeding and genomic technologies aimed at unlocking the unexplored genetic diversity of organisms. Established in 2010, Meiogenix offers innovative solutions such as SpiX technology, which enhances homologous recombination in specific regions of the genome, and PhoeniX, a non-genetically modified method that facilitates meiotic recombination in hybrid diploid or polyploid yeast cells. These advancements enable the company to support the development of new products that address pressing global food and industrial challenges, expanding natural biodiversity through natural breeding techniques.
Safe Orthopaedics is a medical technology company based in Éragny-sur-Oise, France, specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers a range of products, including the SteriSpine PS kit for spinal fractures and degenerative conditions, and the SteriSpine VA platform for kyphoplasty and cement systems. Additionally, Safe Orthopaedics provides ready-to-use instrumentation for lumbar and cervical cages, featuring products such as Cedar, Elm, and Walnut. With a focus on spinal surgery, the company serves both the French and international markets.